1. FDA Committee Votes 6-6 on Durect's Non-Opioid Pain Drug — Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020 — Novo Nordisk's Ozempic wins FDA label boost with CV indication — See more on our front page news TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Great Idea Wrong People

Discussion in 'Auriga Labs' started by Anonymous, Jun 24, 2011 at 3:22 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Auriga had a great idea, they just had the wrong people, especially Richard and Phil. What a pair.
     

  2. Anonymous

    Anonymous Guest

    Agreed. A great idea poorly executed. The assumption that something that sells in Europe will automatically sell in the United States was a huge miscalculation. They also had cold medication that they knew was going to be pulled from the market.